Mimedx (MDXG) EPS (Weighted Average and Diluted) (2012 - 2026)
Mimedx recorded quarterly EPS (Weighted Average and Diluted) of -$0.07 in Q1 2026, down 170.0% quarter-over-quarter from $0.1 in Q4 2025, and down 240.0% year-over-year from $0.05 in Q1 2025.
Mimedx's EPS (Weighted Average and Diluted) history runs 15 years deep, the most recent figure standing at -$0.07 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 240.0% year-over-year to -$0.07; the TTM figure through Mar 2026 stood at $0.2 (down 25.93% YoY), while the FY2025 annual figure was $0.32, up 14.29% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.07 for Q1 2026 at Mimedx, down from $0.1 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.37 in Q4 2023 to a low of -$0.11 in Q1 2022.
- A 5-year average of $0.04 and a median of $0.05 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 266.67% in 2022 and jumped 1100.0% in 2024, its largest moves.
- Mimedx's EPS (Weighted Average and Diluted) stood at $0.07 in 2022, then soared by 428.57% to $0.37 in 2023, then plunged by 86.49% to $0.05 in 2024, then jumped by 100.0% to $0.1 in 2025, then sank by 170.0% to -$0.07 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.07, $0.1, and $0.11 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.07 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.05 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.05 |
| Jun 30, 2024 | 0.12 |
| Mar 31, 2024 | 0.06 |
| Dec 31, 2023 | 0.37 |
| Sep 30, 2023 | 0.06 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | -0.06 |
| Dec 31, 2022 | 0.07 |
| Sep 30, 2022 | -0.09 |
| Jun 30, 2022 | -0.11 |
| Mar 31, 2022 | -0.11 |
| Dec 31, 2021 | -0.02 |
| Sep 30, 2021 | -0.04 |
| Jun 30, 2021 | -0.03 |
| Mar 31, 2021 | -0.09 |
| Dec 31, 2020 | -0.17 |
| Sep 30, 2020 | -0.48 |
| Jun 30, 2020 | -0.08 |
| Mar 31, 2020 | -0.04 |
| Dec 31, 2019 | -0.07 |
| Sep 30, 2019 | 0.11 |
| Jun 30, 2019 | -0.16 |
| Mar 31, 2019 | -0.12 |
| Dec 31, 2018 | -0.34 |
| Sep 30, 2018 | 0.00 |
| Jun 30, 2018 | 0.02 |
| Mar 31, 2018 | 0.04 |
| Dec 31, 2017 | 0.04 |
| Sep 30, 2017 | 0.37 |
| Jun 30, 2017 | 0.09 |
| Mar 31, 2017 | 0.05 |
| Dec 31, 2016 | 0.05 |
| Sep 30, 2016 | 0.03 |
| Jun 30, 2016 | 0.02 |
| Mar 31, 2016 | 0.01 |
| Dec 31, 2015 | 0.11 |
| Sep 30, 2015 | 0.06 |
| Jun 30, 2015 | 0.05 |
| Mar 31, 2015 | 0.04 |
| Dec 31, 2014 | 0.03 |
| Sep 30, 2014 | 0.03 |
| Jun 30, 2014 | 0.00 |
| Mar 31, 2014 | -0.01 |
| Dec 31, 2013 | -0.01 |
| Sep 30, 2013 | 0.00 |
| Jun 30, 2013 | -0.01 |
| Mar 31, 2013 | -0.02 |
| Dec 31, 2012 | -0.01 |
| Sep 30, 2012 | -0.05 |
| Jun 30, 2012 | -0.01 |
| Mar 31, 2012 | -0.01 |